Shennon Biotechnologies (ShennonBio) is a San Francisco biotechnology company founded in 2021 that develops precision immunotherapies for solid tumors through an integrated discovery engine combining target identification, ultra-high-throughput single-cell functional screening, computational binder design and AI-driven safety prediction. Its TCELERATOR platform profiles more than 10 million single-cell interactions at once, and its pipeline of antibody- and TCR-based T-cell engager programs targets small cell lung cancer, ovarian cancer and hepatocellular carcinoma. The company operates laboratory space near UCSF Mission Bay and is led by CEO Cyril Konto alongside founder Li Sun, who serves as President and Chief Technology Officer.
1
Round
1
Industry
3
Tags
Sep 14, 2026
Latest raise
Funding activity · 1 round
Sep 14, 2026
$12M
Series A
Shennon Biotechnologies Closes $12M Series A Shennon Biotechnologies, a San Francisco based biotechnology company developing precision immunotherapies for soli…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
